I don’t feel like this PR is related to CYDY and
Post# of 148320
“The client is an early stage development company with a high potential early stage asset.” - CYDY is not an early stage company and leronlimab is not an early stage asset
“and will increase to $301 million US when the client obtains approval for the product.” - Isn’t the deal with $1 billion?